BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 23000327)

  • 21. Multidimensional Prognostic Index and pro-adrenomedullin plasma levels as mortality risk predictors in older patients hospitalized with community-acquired pneumonia: a prospective study.
    Pilotto A; Dini S; Veronese N; Daragjati J; Miolo M; Mion MM; Fontana A; Lo Storto M; Zaninotto M; Bragato G; Cella A; Carraro P; Addante F; Copetti M; Plebani M
    Panminerva Med; 2018 Sep; 60(3):80-85. PubMed ID: 29546738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia.
    Claessens YE; Mathevon T; Kierzek G; Grabar S; Jegou D; Batard E; Loyer C; Davido A; Hausfater P; Robert H; Lavagna-Perez L; Bernot B; Plaisance P; Leroy C; Renaud B
    Intensive Care Med; 2010 May; 36(5):799-809. PubMed ID: 20232049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
    Ugajin M; Yamaki K; Hirasawa N; Yagi T
    Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis.
    Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A
    J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission.
    Gonzalez Del Castillo J; Wilson DC; Clemente-Callejo C; Román F; Bardés-Robles I; Jiménez I; Orviz E; Dastis-Arias M; Espinosa B; Tornero-Romero F; Giol-Amich J; González V; Llopis-Roca F;
    Crit Care; 2019 Oct; 23(1):335. PubMed ID: 31665092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia.
    Schuetz P; Litke A; Albrich WC; Mueller B
    Curr Opin Infect Dis; 2013 Apr; 26(2):159-67. PubMed ID: 23434895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of procalcitonin in community-acquired pneumonia.
    Schuetz P; Suter-Widmer I; Chaudri A; Christ-Crain M; Zimmerli W; Mueller B;
    Eur Respir J; 2011 Feb; 37(2):384-92. PubMed ID: 20595156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble thrombomodulin to evaluate the severity and outcome of community-acquired pneumonia.
    Yin Q; Liu B; Chen Y; Zhao Y; Li C
    Inflammation; 2014 Aug; 37(4):1271-9. PubMed ID: 24573987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score.
    Travaglino F; De Berardinis B; Magrini L; Bongiovanni C; Candelli M; Silveri NG; Legramante J; Galante A; Salerno G; Cardelli P; Di Somma S
    BMC Infect Dis; 2012 Aug; 12():184. PubMed ID: 22874067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index.
    Masiá M; Gutiérrez F; Shum C; Padilla S; Navarro JC; Flores E; Hernández I
    Chest; 2005 Oct; 128(4):2223-9. PubMed ID: 16236878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia?
    Pereira JM; Teixeira-Pinto A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
    J Crit Care; 2013 Dec; 28(6):970-4. PubMed ID: 24216331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MR-proANP, MR-proADM, and PCT in Patients Presenting with Acute Dyspnea in a Medical Emergency Unit.
    Heining L; Giesa C; Ewig S
    Lung; 2016 Apr; 194(2):185-91. PubMed ID: 26748496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.
    Krüger S; Ewig S; Marre R; Papassotiriou J; Richter K; von Baum H; Suttorp N; Welte T;
    Eur Respir J; 2008 Feb; 31(2):349-55. PubMed ID: 17959641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients.
    Cinar O; Cevik E; Acar A; Kaya C; Ardic S; Comert B; Yokusoglu M; Bilgi C; Meisner M; Madsen T
    Am J Emerg Med; 2012 Nov; 30(9):1915-20. PubMed ID: 22742951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of pro-adrenomedullin, procalcitonin and C-reactive protein in predicting outcome of febrile urinary tract infection.
    van der Starre WE; Zunder SM; Vollaard AM; van Nieuwkoop C; Stalenhoef JE; Delfos NM; Van't Wout JW; Spelt IC; Blom JW; Leyten EM; Koster T; Ablij HC; van Dissel JT
    Clin Microbiol Infect; 2014 Oct; 20(10):1048-54. PubMed ID: 25039648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review.
    Cavallazzi R; El-Kersh K; Abu-Atherah E; Singh S; Loke YK; Wiemken T; Ramirez J
    Respir Med; 2014 Nov; 108(11):1569-80. PubMed ID: 25448309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia.
    Menéndez R; Martínez R; Reyes S; Mensa J; Filella X; Marcos MA; Martínez A; Esquinas C; Ramirez P; Torres A
    Thorax; 2009 Jul; 64(7):587-91. PubMed ID: 19131448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia.
    Kasamatsu Y; Yamaguchi T; Kawaguchi T; Tanaka N; Oka H; Nakamura T; Yamagami K; Yoshioka K; Imanishi M
    Respirology; 2012 Feb; 17(2):330-6. PubMed ID: 22059525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mortality prediction using serum biomarkers and various clinical risk scales in community-acquired pneumonia.
    Kim MW; Lim JY; Oh SH
    Scand J Clin Lab Invest; 2017 Nov; 77(7):486-492. PubMed ID: 28678546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*.
    Debiane L; Hachem RY; Al Wohoush I; Shomali W; Bahu RR; Jiang Y; Chaftari AM; Jabbour J; Al Shuaibi M; Hanania A; Pravinkumar SE; Schuetz P; Raad I
    Crit Care Med; 2014 Dec; 42(12):2500-7. PubMed ID: 25083975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.